Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053599 · ClinicalTrials.gov registry record · Phase 3
Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study
A Phase 3 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00053599 is a Phase 3 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 400 participants.
The verdict
NCT00053599, a Phase 3 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
CLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD). Statins are commonly used to treat high cholesterol levels, which increase the risk of heart disease and stroke.
Interventions
- DRUG Simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2002-12 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053599
The ClinicalTrials.gov registry entry for NCT00053599 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Simvastatin is the first listed.
NCT00053599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053599 about?
NCT00053599 is a clinical study titled "Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study". CLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD). Statins are commonly used to treat high cholesterol levels, which increase the risk of heart disease and stroke.
What is the current status of trial NCT00053599?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2002-12. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00053599?
The interventions under investigation include: Simvastatin (DRUG).
Who is sponsoring clinical trial NCT00053599?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.